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OBJECTIVES: To determine the prevalence of glaucomatous risk
factors (RFs) in glaucoma patients in a managed-care practice.
METHODS: Retrospective review of medical records of 1189
glaucoma patients. Diagnosis and documentation information of
15 RFs reported to be associated with glaucoma progression
were collected. The 15 RFs included age >70, family history,
African American origin, high intraocular pressure (IOP),
increase cup/disc (C/D) ratio, poor visual ﬁeld score, disc hem-
orrhage, pseudoexfoliation sign, low central corneal thickness
(CCT), high myopia, cardiovascular disease, systemic hyperten-
sion, diabetes mellitus (DM), migraine headache, and
vasospasm. The average risk score for the population was cal-
culated using the predictive model based on 5 risk factors (age,
IOP, CCT, C/D ratio, VF score, and DM) derived from Medeiros
et al. (2005), where a higher score indicates greater risk.
RESULTS: A total of 1182 of 1189 patients for which medical
records were available had a clear diagnosis in the charts. Mean
age (63.0 ± 11.9 years) and the average IOP (18.3 ± 4.7 mm Hg)
was calculated. Average value of C/D ratio was 0.52 ± 0.18,
pattern standard deviation was 2.59 ± 1.99 dB, and CCT was
552 ± 34 microns. The glaucomatous RF with the highest inci-
dence was systemic hypertension (39.0%), followed by age >70
(27.2%), DM (23.6%), African American origin (23.0%), and a
family history of glaucoma (18.2%). An average risk score was
42 for this population. CONCLUSION: Three of the ﬁve most
prevalent glaucomatous RFs from this population were not
included in the predictive model. The prevalence of RFs and risk
scores may be compared with a non-glaucoma patient popula-
tion or a population of glaucoma patients without glaucomatous
RFs to determine the relative risk difference. Existing models for
calculating glaucoma risk scores do not consider several impor-
tant risk factors, and these variables should be considered in
future calculation models.
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VISUAL IMPAIRMENT
Kymes SM1, Zhou Z2, Plotzke M1, Fain J3
1Washington University, Saint Louis, MO, USA, 2Pﬁzer Inc, Bridgewater,
NJ, USA, 3Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: We measured increased non-vision cost for 
progression to visual loss due to glaucoma. METHODS: We 
analyzed a random 5% sample of Medicare beneﬁciaries
(1999–2003). Presence the ICD-9 code, 365.xx, in a 1999 claim
was considered evidence of glaucoma. Inclusion required sur-
vival from 1999–2003. Moderate visual loss was deﬁned as
severe impairment in the worst seeing-eye (ICD-9 > 369.60).
Severe visual loss was deﬁned as severe impairment in best
seeing-eye (ICD-9 369.10 to 369.41). Blindness was deﬁned as
near total to profound impairment in both eyes (ICD-9 369.0 to
369.09). We identiﬁed those who reported depression, injury and
living in long-term care settings. We report the mean total
medical costs for each group and the increased risk of depres-
sion or injury, and living in an institutional setting associated
with progression. RESULTS: In total, 57,664 beneﬁciaries were
reported as having glaucoma. 54,596 did not experience severe
impairment in either eye, while 3068 beneﬁciaries (5.3%)
reported severe impairment in at least one eye during the ﬁve
year period. Increased visual impairment was associated with
higher overall medical costs in 2003. Those who were blind had
the highest cost of those who did not progress ($11,568). Those
who progressed from glaucoma to blindness had the highest
overall cost ($16,109). Among those who progressed to vision
loss, progression to blindness had the highest incremental cost
($5510). Those who progressed to any vision loss were more
likely to be diagnosed with depression or injury, or to be in long-
term care or skilled nursing facility than those who did not,
including those who had visual impairment at the beginning 
of the period. CONCLUSION: Among people with glaucoma,
progression to loss of visual function in even a single eye 
leads to higher medical costs during progression. A substantial
portion of this cost is associated with avoidable conditions and
institutionalization.
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OBJECTIVES: The purpose of this study was to estimate the
total and incremental costs associated with antibiotic treatments
for acute otitis media (AOM). METHODS: Persons over age 18
were identiﬁed in the Marketscan databases July–December
2004. We identiﬁed AOM episodes for patients with claims for
ICD9 codes 381.0X, 381.4X, 382.0X and 382.9X. We then
identiﬁed the most frequently antibiotics prescribed as initial
treatment for an AOM episode. Logistic regression estimated a
propensity score for each patient; which was the predicted prob-
ability of using telithromycin. Patients were then matched
according to this probability. Exponential conditional means
models (ECM) were speciﬁed, controlling signiﬁcant variables
after the propensity score matching (demographics and comor-
bidities). These models allowed the incremental costs to be esti-
mated for treatment of a reference drug, telithromycin, relative
to other antibiotics. RESULTS: The most common initial antibi-
otic treatments compared to telithromycin for AOM (n = 243
episodes) were amoxicillin, azithromycin, cefdinir, cefprozil and
levoﬂoxacin, moxiﬂoxacin. The mean length of an AOM episode
was 8.1 to 13.0 days. Mean total expenditures among the
episodes was $196, with a range of $165 to $244. Multivariate
ECM models were ﬁtted and showed signiﬁcant incremental cost
reductions per episode associated with telithromycin relative to:
cefdinir (−$64, p < 0.001), cefprozil (−$65, p < 0.001) and clar-
ithromycin (−$47, p < 0.001). CONCLUSION: The results of
this study show that the costs differed among episodes of AOM
by the initiating antibiotic. Use of propensity score matching and
ECM regression controlled for intra-episode differences, so the
incremental costs differences may be attributed to other factors
such as disease severity. Although different antibiotics may be in
the same drug class, the choice of the initiating antibiotic for an
AOM episode in this adult population clearly had ﬁnancial
implications.
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OBJECTIVES: The objective of this analysis was to determine
the net economic beneﬁt to society from a SN60WF new tech-
nology intraocular lens (NTIOL) with an aspheric surface used
for the treatment of cataracts. METHODS: The incremental
costs of the aspheric SN60WF NTIOL were derived from the
additional $50 reimbursement paid by the U.S. Centers for
Medicare and Medicaid Services (CMS) for implantation of
NTIOLs in Medicare beneﬁciaries with cataracts. The economic
beneﬁts of the SN60WF were based on projected cost savings
from averted rear-end passenger vehicle collisions in the recipi-
ent population due to improved functional vision. Improved
functional vision was established using driving simulation results
comparing SN60WF recipients to patients implanted with a con-
ventional monofocal intraocular lens. A societal perspective and
a ten year time frame were used in the analysis. All costs and
beneﬁts were discounted at 3%. RESULTS: The incremental
costs to CMS for SN60WF implantation over the next decade
were estimated at $60 million U.S. dollars (USD). Driving sim-
ulation results indicated that SN60WF recipients performed
better than the control group in 34 of 36 driving tests. Further-
more SN60WF recipients were able to detect and identify poten-
tial road hazards from 0.5 to 1 second before the control patients
in 12 of the 36 tests. The economic beneﬁts from averted rear-
end passenger vehicle collisions were estimated in the range of
$105 to $158 million USD for the same 10 year period. Conse-
quently, the net economic beneﬁt to society was estimated
between $45 and $98 million USD over the next decade. A
threshold analysis revealed that a reduction in rear-end collisions
of 31% within the SA60WF recipient population was enough 
to offset the incremental NTIOL costs associated with the new
lens. CONCLUSION: Implantation of the NTIOL SN60WF in
cataract patients provides a net economic beneﬁt to society far
in excess of its incremental costs.
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OBJECTIVES: The objective of this study was to determine the
relative cost-effectiveness of three multifocal intraocular lenses
(IOLs) commonly implanted in cataract patients. METHODS: A
cost-effectiveness analysis was performed to determine the cost-
effectiveness ratios for the following three multifocal intraocular
lenses available in the U.S. health care market: an apodized dif-
fractive multifocal (ADM) IOL, a zonal refractive multifocal
(ZRM) IOL and an accommodating posterior chamber (APC)
IOL. The measure of effectiveness used was vision adjusted life
years (VALYs). VALYs are the product of the uncorrected near
visual acuity (UCNVA) provided by the IOLs and the average
life expectancy of the cataract patients. UCNVA, expressed in
decimal notation, and cost estimates were taken from the
medical literature. UCNVA was chosen as the measure of effect
because it is generally accepted that uncorrected distance visual
acuity outcomes are similar between the 3 alternative IOLs. The
economic perspective was that cataract patients enrolled in the
United States Medicare program. Only the direct incremental
costs of the multifocal IOLs were considered in the analysis. The
time span of the analysis was 14.2 years based on cataract
patients’ average life expectancy (ALE). No cost discounting was
performed because all incremental costs considered accrue in
year one. RESULTS: The average cost to patients for bilateral
multifocal IOL implantation was estimated at $4000. The
average UCNVAs, expressed in Snellen decimal notation, for the
ADM, ZRM and APC IOLs were 0.80, 0.57 and 0.7, respec-
tively. The VALY products of UCNVA and ALE for the ADM,
ZRM and APC IOLs were 11.36, 9.94 and 8.09 respectively. The
resultant VALY cost-effectiveness ratios for the ADM, ZRM and
APC IOLs were $352.11, $494.19 and $402.41, respectively.
CONCLUSION: Given the incremental cost associated with
multifocal IOLs the ADM IOL provides cataract patients with
the best value for their money.
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OBJECTIVES: To compare the effectiveness and related costs of
prostaglandins (PG) associated with either alpha-2 agonists or
carbonic anhydrase inhibitors (CAI), in the treatment of glau-
coma, according to the UK General Practitioner Research Data-
base (UK-GPRD). METHODS: Data were extracted on patients
diagnosed with ocular hypertension or glaucoma who had
undergone topical treatment, surgery or laser therapy. A subse-
quent selection identiﬁed patients receiving prostaglandins asso-
ciated with an alpha-2 agonist (PG + alpha-2) or CA inhibitor
(PG + CAI). Treatment failure was deﬁned as a prescription
change (addition or removal of a topical treatment). Times to
treatment failure were compared using an adjusted Cox model.
Drugs, clinic visits and glaucoma procedures were collected over
a ﬁxed period for a cost minimization analysis, performed from
the NHS perspective. RESULTS: Data on 56,612 patients were
extracted and 39,808 had received at least one topical prescrip-
tion for glaucoma. The treatment for 1384 patients was PG +
alpha-2 and for 4792 patients PG + CAI. Patient characteristics
did not differ signiﬁcantly between the two populations. The
average age at diagnosis was 69.0 years and 47.6% were male.
Treatment failure within one year occurred for 70.0% of patients
receiving PG + alpha-2 and for 59.5% receiving PG + CAI (p <
0.001). The hazard ratio 0.822 for failure, after adjusting on age,
gender, and comorbidities, was less with PG + CAI (p < 0.001)
than PG + alpha-2. The adjusted cost of PG + alpha-2 treatment
(£441 p.a.) did not differ signiﬁcantly (p = 0.23) from PG + CAI
(£413). CONCLUSION: According to UK GPRD information,
PG + CAI is more efﬁcient than PG + alpha-2 for treating glau-
coma patients. Patients remained under treatment longer with
PG + CAI, than with PG + alpha 2, at a similar cost.
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OBJECTIVES: To compare the effectiveness and costs of beta-
blockers, combined with alpha-2 agonists or carbonic anhydrase
inhibitors (CAI), as replacements for failed ﬁrst-line treatments
in glaucoma, according to the UK General Practitioner Research
Database (UK-GPRD). METHODS: Data on treated ocular
hypertension or glaucoma patients (topical, surgical or laser
treatments) were extracted. Target patients were prescribed beta-
blockers with alpha-2 agonists or CA inhibitors as replacements
for failed treatment regimens. A subsequent change of prescrip-
tion (addition or removal of a topical treatment) constituted a
